Нейролайф · DCP China
FRDA

FRDA — where it's treated in the network

Most families come to the network case manager with FXN genetic testing already confirmed and a cardiologist already monitoring hypertrophic cardiomyopathy. Since 2023 the first disease-modifying drug — omaveloxone (Skyclarys) — has been available alongside symptomatic care. The case manager will help compare network clinics by ataxia-specific work (Frenkel exercises, balance, hydrotherapy), the cardiac monitoring format during the course and family logistics, then schedule the course around the main medical follow-up.

8188+
patients
from 4 weeks + regular cycles
course
About the condition

What is Friedreich Ataxia?

Friedreich's ataxia is an inherited progressive neurodegenerative disease that affects cerebellar pathways, peripheral nerves and the heart. The cause is a trinucleotide repeat expansion in the FXN gene. ICD-10 codes it as G11.1 (early-onset cerebellar ataxia). It occurs in roughly 1 of every 50,000; first signs usually appear at age 5–18 (gait, coordination). Cardiomyopathy is a key driver of life expectancy.

Families usually reach the network case manager with the diagnosis already confirmed by FXN gene analysis. Since 2023, omaveloxone (Skyclarys) has been available — an FDA-approved drug. The rehabilitation side focuses on motor function, balance, coordination, and cardiopulmonary follow-up. Details on causes, symptoms and the program are in the expandable blocks below.

Frequently asked questions

Frequently asked questions about Friedreich Ataxia

Does rehabilitation help in Friedreich ataxia?

What is Skyclarys and can it be combined?

Should physical load be restricted with cardiomyopathy?

Is FRDA inherited?

Talk to a network coordinator

The coordinator reviews your documents and suggests matching clinics. We reply on Telegram and WhatsApp within an hour on workdays.

Leave a request

We use cookies and analytics to improve the website experience. Privacy Policy